Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical

Form 483 issued March 23, 2017 · Los Angeles, California

Inspection
Mar 13 – Mar 23, 2017
Observations
4
Pages
7
FEI number
3013341563

In short: On March 23, 2017, FDA issued a Form 483 with 4 observations to Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical in Los Angeles, California (FEI 3013341563) after an inspection that ran Mar 13 – Mar 23, 2017. The investigators were Brian P. Murphy, Macedonio D. Doolan and Thach-Nga Q. Luu.

What FDA observed

Preview: the opening words of each observation
  1. 01

    Observation 1: scanned text, readable in the full document.

  2. 02

    Observation 2: scanned text, readable in the full document.

  3. 04

    Observation 4: scanned text, readable in the full document.

1 more observation

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical?

FDA listed 4 observations on this Form 483. The opening words of each observation are shown on this page.

Who inspected Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical?

Brian P. Murphy, Macedonio D. Doolan and Thach-Nga Q. Luu are named on this Form 483, for the inspection of Mar 13 – Mar 23, 2017. Each investigator has a profile showing what they cite most.

When was Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical inspected by FDA?

The inspection ran Mar 13 – Mar 23, 2017, and the Form 483 is dated March 23, 2017.

How do I get the full Form 483 for Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free